Preclinical evidence demonstrates that chronic EGFR inhibition triggers non-genetic resistance through TPX2-mediated Aurora kinase A (AURKA) activation; thus, combining an AURKA inhibitor with third-generation EGFR-TKI osimertinib can overcome acquired resistance in NSCLC [30]. Here, TPX2 is linked to non-small cell lung carcinoma.